艾迪注射液联合化疗对中晚期NSCLC患者外周血肿瘤细胞CK19-mRNA表达的影响

目的探讨艾迪注射液联合化疗对中晚期非小细胞肺癌（NSDLD）患者外周血肿瘤细胞细胞角蛋白（CK19）-mRNA表达的影响。方法将40例中晚期NSCLC患者随机分为两组，观察组22例用紫杉醇、顺铂化疗＋艾迪注射液治疗，对照组18例用紫杉醇、顺铂化疗。用逆转录聚合酶链式反应技术检测两组化疗2周期后外周血肿瘤细胞CK19-mRNA相对表达量，并观察其疗效及生存期。结果两组治疗前后比较、观察组与对照组比较，CK19-mRNA相对表达量均有统计学差异（P均〈0．05）；观察组化疗有效率及生存率均优于对照组（P〈0．05）。结论艾迪注射液可能通过下调NSDLD患者外周血肿瘤细胞CK19-mRNA表达量而起到化疗增效的作用。

Effect of AiDi injection combined with chemotherapy on mRNA expression of CK-19 in peripheral blood turmor cell of advanced non-small cell lung cancer

Objective To investigate the effect of AiDi injection combined with chemotherapy on mRNA expression of CK-19 in peripheral blood tumor cell of advanced non-small cell lung cancer（NSCLC）. Methods Forty patients with advanced NSCLC were randomly divided into the study group（ n = 22 ,treated with AiDi injection combined with chemotherapy） and the control group（ n = 18 ,treated with chemotherapy）. The regimen of chemotherapy was paclitaxel plus carboplatin. CK-19 mRNA level in peripheral blood turmor cell in advanced NSCLC was determined after 2 cycles by relative quantity RT-PCR. The efficacy and overall survival of each group were observed. Results The levels of CK-19 mRNA in both of two groups were significantly decreased（ P 〈 0.05 ）, as compared with that before chemotherapy. The study group reduced the level of CK-19 mRNA more effectively than the control group（P 〈0.05）. The overall response rate and overall survival of the study group were better than the control group （P 〈 0. 05）. Condusion A/Di injection can enhance the therapeutic effect probably by reducing the level of CK-19 mRNA in peripheral blood turmor cell of NSCLC.